Keizo Koya - Net Worth and Insider Trading

Keizo Koya Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Keizo Koya owns 1 companies in total, including Madrigal Pharmaceuticals Inc (MDGL) .

Click here to see the complete history of Keizo Koya’s form 4 insider trades.

Insider Ownership Summary of Keizo Koya

Ticker	Comapny	Transaction Date	Type of Owner
MDGL	Madrigal Pharmaceuticals Inc	2007-02-05	Sr. VP & Drug Development

Keizo Koya Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Keizo Koya Ownership Network

Ownership Network List of Keizo Koya

No Data

Ownership Network Relation of Keizo Koya

Keizo Koya Owned Company Details

What does Madrigal Pharmaceuticals Inc do?

Who are the key executives at Madrigal Pharmaceuticals Inc?

Keizo Koya is the Sr. VP & Drug Development of Madrigal Pharmaceuticals Inc. Other key executives at Madrigal Pharmaceuticals Inc include director & President and CEO William John Sibold , Senior VP & Chief Pharma Dev. Robert E. Waltermire , and director & 10 percent owner Fred B Craves .

Madrigal Pharmaceuticals Inc (MDGL) Insider Trades Summary

Over the past 18 months, Keizo Koya made no insider transaction in Madrigal Pharmaceuticals Inc (MDGL). Other recent insider transactions involving Madrigal Pharmaceuticals Inc (MDGL) include a net purchase of 424,685 shares made by Baker Bros. Advisors Lp , a net sale of 12,736 shares made by Robert E. Waltermire , and a net sale of 21,000 shares made by Richard S Levy .

In summary, during the past 3 months, insiders sold 16,363 shares of Madrigal Pharmaceuticals Inc (MDGL) in total and bought 0 shares, with a net sale of 16,363 shares. During the past 18 months, 313,930 shares of Madrigal Pharmaceuticals Inc (MDGL) were sold and 424,685 shares were bought by its insiders, resulting in a net purchase of 110,755 shares.

Madrigal Pharmaceuticals Inc (MDGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Madrigal Pharmaceuticals Inc Insider Transactions

No Available Data

Keizo Koya Mailing Address

Above is the net worth, insider trading, and ownership report for Keizo Koya. You might contact Keizo Koya via mailing address: C/o Synta Pharmaceuticals Corp., 45 Hartwell Avenue, Lexington Ma 02421.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.